Forgot your password?
New user?
Nanoparticle fear over anti-odour socks
Fragment-based Lead Discovery Conference 2008
test conference
Document Actions
Discovery & Selection of Successful Drug Candidates
May 4 – 7, 2008 | The Mark Hopkins InterContinental | San Francisco, CA
| Type | Conference |
|---|---|
| Language | English |
| Date |
May 4, 2008
to May 7, 2008 |
| Venue |
The Mark Hopkins InterContinental 999 California St San Francisco, CA 94108 US |
| Chemistry Specialties |
|
| Chemistry Techniques |
|
| Contact |
ACS 1155 Sixteenth Street, NW Washington, DC , 20036 US (800) 227-5558 acsprospectives@acs.org |
| Add event to calendar |
vCal (Windows, Linux)
iCal (Mac OS X)
|
The 4th annual ACS ProSpectives "Discovery and Selection of Successful Drug Candidates” is again chaired by Dr. Andrew Combs, Executive Director of Incyte, and Dr. Greg Roth, Associate Professor and Director of Medicinal Chemistry and Pharmacology at The Burnham Institute for Medical Research. Together they have gathered another group of highly regarded pharmaceutical industry scientists who will lecture and collectively present about 20 case studies over the course of the two-and-a half-day program. This conference is geared specifically for medicinal chemists and focuses on the key drivers for discovery of new drug candidates. The program is comprised of four sessions that address the key areas of interest for the practicing medicinal chemist. They are: * Hits to Leads * Structure-Based Drug Design * ADME – Addressing Permeability Issues * Efficacy vs Toxicity In each session, four speakers will lecture on their research in a case study format, specifically addressing and providing prospective on the session topic. On the last day, three VPs of pharmaceutical companies will present “Prospectives from Industrial Leaders –Pharma Yesterday, Today and Tomorrow.” This session will feature presentations on small molecule drugs that have been discovered and advanced through proof of concept, or been successfully marketed by their companies. These leaders will share their perspectives on how the compounds were discovered, lessons learned, and how these lessons have been instituted into their company’s current drug discovery processes.